We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+12.84%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.05B
AUM Growth
+$146M
Cap. Flow
-$430M
Cap. Flow %
-8.52%
Top 10 Hldgs %
43.4%
Holding
134
New
26
Increased
24
Reduced
35
Closed
22
Avg Time Held Equity + Options
7.7 quarters
Top 10 Avg Time Held Equity + Options
5.6 quarters
Top 20 Avg Time Held Equity + Options
7.5 quarters
Avg Time Held Equity only
8 quarters
Top 10 Avg Time Held Equity only
5.7 quarters
Top 20 Avg Time Held Equity only
7.9 quarters

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$129M
2
MRK icon
Merck
MRK
+$76.6M
3
GH icon
Guardant Health
GH
+$43.7M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$31.5M
5
QURE icon
uniQure
QURE
+$28.3M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$87M
2
LLY icon
Eli Lilly
LLY
+$65.3M
3
APLS icon
Apellis Pharmaceuticals
APLS
+$61M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$57.8M
5
CI icon
Cigna
CI
+$56.4M

Sector Composition

Rank Sector Weight
1 Healthcare 90.42%
2 Miscellaneous 9.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
EWTX icon
1
Edgewise Therapeutics
EWTX
$3.99B
$489M 9.69%
15,518,492
– –
2021 Q1
20 quarters
ELVN icon
2
Enliven Therapeutics
ELVN
$2.9B
$312M 6.18%
7,959,538
– –
2020 Q1
24 quarters
MDXH icon
3
CALL
MDxHealth
MDXH
$60.8M
$286M 5.67%
+124,306,000
New +$422M
2026 Q1
0 quarters
LLY icon
4
Eli Lilly
LLY
$1.04T
$218M 4.32%
236,800
-64,400
-21% -$65.3M
2023 Q1
12 quarters
SVA
5
DELISTED
Sinovac Biotech, Ltd
SVA
$184M 3.66%
2,718,735
– –
2022 Q2
15 quarters
RCEL icon
6
CALL
Avita Medical
RCEL
$410M
$154M 3.06%
+40,966,100
New +$172M
2026 Q1
0 quarters
BSX icon
7
Boston Scientific
BSX
$63.3B
$149M 2.96%
2,382,100
-37,200
-2% -$2.98M
2014 Q1
48 quarters
SION icon
8
Sionna Therapeutics
SION
$199M
$142M 2.81%
3,530,702
-30,953
-0.9% -$1.18M
2025 Q1
4 quarters
AZN icon
9
AstraZeneca
AZN
$243B
$132M 2.62%
+670,200
New +$129M
2026 Q1
0 quarters
MYGN icon
10
Myriad Genetics
MYGN
$403M
– –
0
– –
2026 Q1
0 quarters
MBX icon
11
MBX Biosciences
MBX
$2.39B
$109M 2.15%
3,637,887
-297,316
-8% -$10.1M
2024 Q3
6 quarters
CRVS icon
12
Corvus Pharmaceuticals
CRVS
$787M
$105M 2.08%
7,165,006
– –
2016 Q1
40 quarters
ARGX icon
13
argenx
ARGX
$50.4B
$100M 1.98%
136,900
-9,100
-6% -$7.12M
2022 Q1
16 quarters
EW icon
14
Edwards Lifesciences
EW
$49.3B
$98.5M 1.95%
1,230,600
-612,300
-33% -$50.5M
2024 Q4
5 quarters
ISRG icon
15
Intuitive Surgical
ISRG
$149B
$96.2M 1.91%
208,700
-54,700
-21% -$27.7M
2013 Q4
49 quarters
CMPX icon
16
Compass Therapeutics
CMPX
$159M
$80.5M 1.6%
15,219,994
– –
2021 Q4
17 quarters
MRK icon
17
Merck
MRK
$352B
$79.8M 1.58%
+663,400
New +$76.6M
2026 Q1
0 quarters
GPCR icon
18
Structure Therapeutics
GPCR
$1.59B
$71.1M 1.41%
1,475,403
+313,600
+27% +$21.5M
2024 Q2
7 quarters
AVBP icon
19
ArriVent BioPharma
AVBP
$801M
$69.8M 1.38%
3,027,328
– –
2024 Q1
8 quarters
IRON icon
20
Disc Medicine
IRON
$2.18B
$68.3M 1.35%
1,067,550
– –
2021 Q1
20 quarters
SPRY icon
21
ARS Pharmaceuticals
SPRY
$403M
$66.6M 1.32%
8,288,510
– –
2020 Q4
21 quarters
CGON icon
22
CG Oncology
CGON
$5.56B
$64.2M 1.27%
948,267
-568,283
-37% -$32.2M
2024 Q3
6 quarters
XENE icon
23
Xenon Pharmaceuticals
XENE
$3.36B
$61.6M 1.22%
1,059,971
+612,771
+137% +$28.2M
2016 Q3
38 quarters
SYK icon
24
Stryker
SYK
$109B
$60M 1.19%
182,500
-142,500
-44% -$51.2M
2020 Q3
22 quarters
BMY icon
25
Bristol-Myers Squibb
BMY
$116B
$56.1M 1.11%
925,000
+150,000
+19% +$8.74M
2025 Q4
1 quarter
1
2 3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2026 Portfolio in Review

As of Q1 2026, OrbiMed held 134 positions worth $5.05B, up 3% from $4.9B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

OrbiMed withdrew a net $430M in Q1 2026, closing 22 positions and reducing 35 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in AstraZeneca worth $132M.

  • OrbiMed's largest Q1 2026 buy was AstraZeneca: 670,200 shares worth $132M.
  • OrbiMed added most to Mineralys Therapeutics in Q1 2026, an estimated $31.5M increase.
  • OrbiMed's biggest Q1 2026 reduction was Eli Lilly, cutting an estimated $65.3M.
  • OrbiMed fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 43% of its $5.05B portfolio in Q1 2026.
  • OrbiMed opened 26 new positions and closed 22 in Q1 2026.
  • OrbiMed's portfolio value rose 3% quarter-over-quarter to $5.05B.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.